- 1 Information about Anidulafungin
- 2 Liver safety of Anidulafungin
- 3 Mechanism of action of Anidulafungin
- 4 FDA approval information for Anidulafungin
- 5 Dosage and administration for Anidulafungin
- 6 Brand name for Anidulafungin
- 7 Side effects of Anidulafungin
- 8 Cost and Coupons - Anidulafungin
- 9 Reviews for Anidulafungin
- 10 Articles on Anidulafungin
- 11 Learn more about Anidulafungin
- 12 Help WikiMD
Information about Anidulafungin
The echinocandins include anidulafungin, caspofungin, and micafungin and are a relatively new class of antifungal agents that are administered parenterally and are used in therapy or prevention of serious, invasive aspergillosis and candidal infections.
Liver safety of Anidulafungin
All three agents can cause transient and asymptomatic serum aminotransferase elevations, and individual instances of acute liver injury have been observed during therapy with these agents, but none has been definitely shown to cause clinically apparent acute drug induced liver injury.
Mechanism of action of Anidulafungin
The echinocandins are a relatively new class of antifungal agents, whose activity is due to inhibition of glucan synthetase, the enzyme that is responsible for synthesis of ß-1, 3-D-glucan, an essential component of the cell wall of filamentous fungi, such as Aspergillus and Candida species. This enzyme inhibition results in alteration in the fungal membrane integrity, followed by cell ballooning and, for Candida cells, lysis.
FDA approval information for Anidulafungin
Three echinocandins are available for use: caspofungin (kas" poe fun' jin), micafungin (mye" ka fun' jin) and anidulafungin (ay nid" ue la fun' jin). Caspofungin was approved for use in the United States in 2001, micafungin in 2005 and anidulafungin in 2006. All three are given intravenously and currently approved for therapy of esophageal candidiasis and for severe, disseminated or invasive candidiasis. Caspofungin is also approved for use as a secondary therapy of invasive aspergillosis and as empirical therapy for presumed fungal infection in febrile, neutropenic patients. Micafungin is also approved for prophylaxis against candidiasis in hematopoietic stem cell transplant recipients. Caspofungin is available under the brand name Cancidas in a formulation for intravenous use, the recommended dose in adults being 70 mg on the first day of treatment followed by 50 or 100 mg daily. Micafungin is available under the brand name of Mycamine in an intravenous formation.
Dosage and administration for Anidulafungin
The recommended dosage being 50 mg daily for prophylaxis and 100 to 150 mg daily for therapy of candidemia.
Brand name for Anidulafungin
Anidulafungin is available under the brand name of Eraxis in intravenous formulations and == Dosage and administration for Anidulafungin == The recommended dosage for disseminated candidal infection is 200 mg on day 1 followed by 100 mg daily. The echinocandins are administered intravenously in a slow infusion over one hour (to decrease the risk of acute infusion reactions).
Side effects of Anidulafungin
The following drugs are antifungal agents:
- Amphotericin B
Cost and Coupons - Anidulafungin
Reviews for Anidulafungin
Articles on Anidulafungin
- UpToDate on Anidulafungin
- NIH NLH drug info on Anidulafungin
- Read Wikipedia's article on Anidulafungin
Learn more about Anidulafungin
Find something you can improve? Join WikiMD as an an editor and help improve this page or others.
|Wikimedia Commons has media related to Drugs.|